📰 Nutrient Absorption News
Page 3 - Nutrient Absorption News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nutrient Absorption. Real-time updates on events, politics, business and more.
August 15, 2023
SynoGut is a meticulously crafted dietary supplement designed to address the complexities of digestive health.
July 29, 2023
Dr Kanchankumar Bhagyawant, Consultant Paediatrician and Neonatologist, In charge-NICU & PICU, Ruby Hall Clinic explains all you need to know about ORS
July 6, 2023
Discover whether babies can consume chia seeds benefits and precautions. Explore the role of chia seeds in improving overall well-being.
June 30, 2023
Discover how carefree people are conquering unexpected knee pain and joint woes with the rising popularity of Hydrolyzed Collagen Type 2 supplements.
June 7, 2023
Grapes are known to contain dietary fibre, polyphenols and other bioactive compounds that can have positive effects on gut health. Dietary fibre in grapes can act as a prebiotic. Additionally, polyphenols like resveratrol have potential prebiotic-like effects by promoting the growth of beneficial gut bacteria, says Dr Priyanka Rohatgi, Chief Nutritionist, Apollo Hospitals
May 6, 2023
Issuer: Immunic, Inc. / Key word(s): Study/Conference Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action 06.05.2023
May 6, 2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
May 4, 2023
Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders 04.05.2023 / 12:30 CET/CEST The issuer is solely responsib...
May 4, 2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
May 4, 2023
Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic